Company intelligence / Profile preview

Supratek Pharma

Pointe-Claire, Quebec, Canadair.darebioscience.com ↗

Ownership: Private
Development stage: Other

Overview

Supratek Pharma develops novel nanomedicine-based therapies to overcome drug resistance and metastasis in cancer. Its lead candidate, SP1049C—a doxorubicin-poloxamer nanoparticle—has shown improved efficacy against chemoresistant tumors and received orphan drug designation from the FDA for esophageal carcinoma. The company has seven clinical-stage proprietary products targeting major unmet needs in oncology, especially late-stage metastatic disease. Their next-in-line product, SP-MET-X1, represents a new class based on a newly discovered pathway involved in metastasis formation.

Therapeutic areas: Oncology
Modalities: NanoparticleSmall moleculePolymer-drug conjugate therapy
Industry: Biotech

Drug pipeline

1 asset

SP1049C

Unknown

Beyond the preview

Go deeper on Supratek Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Supratek Pharma.

Explore the full profile